The HCPLive conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.
In the last 20 years, most were adult studies which indicates a need for pediatric research activity, especially considering the potential that targeted therapies have for treating chronic kidney disease in children.
Extended induction treatment with upadacitinib 45 mg led to achievement of clinical response in a clinically meaningful proportion of patients with ulcerative colitis who do not respond to 8 weeks of induction therapy.
RBX2660 reduced clostridioides difficile infection recurrence at 8 weeks, with a sustained clinical response through 6 months, in an open-label phase 3 cohort of patients representative of real-world clinical practice.
Treatment with guselkumab resulted in greater improvements across key clinical and endoscopic/histologic outcome measures at week 12 compared with placebo in patients with moderately to severely active ulcerative colitis with or without a history of inadequate response or intolerance to advanced therapy.
Patients with ulcerative colitis treated with combination induction therapy with guselkumab plus golimumab followed by guselkumab monotherapy achieved higher rates of the several end points at week 38 as compared to either guselkumab or golimumab alone.